These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22163141)

  • 1. Valvular heart disease with the use of fenfluramine-phentermine.
    Surapaneni P; Vinales KL; Najib MQ; Chaliki HP
    Tex Heart Inst J; 2011; 38(5):581-3. PubMed ID: 22163141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valvular heart disease associated with fenfluramine-phentermine.
    Connolly HM; Crary JL; McGoon MD; Hensrud DD; Edwards BS; Edwards WD; Schaff HV
    N Engl J Med; 1997 Aug; 337(9):581-8. PubMed ID: 9271479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.
    Gardin JM; Schumacher D; Constantine G; Davis KD; Leung C; Reid CL
    JAMA; 2000 Apr; 283(13):1703-9. PubMed ID: 10755496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The longitudinal effects of fenfluramine-phentermine use.
    Fleming RM; Boyd LB
    Angiology; 2007; 58(3):353-9. PubMed ID: 17626991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine.
    Gardin JM; Weissman NJ; Leung C; Panza JA; Fernicola D; Davis KD; Constantine GD; Reid CL
    JAMA; 2001 Oct 24-31; 286(16):2011-4. PubMed ID: 11667938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.
    Kancherla MK; Salti HI; Mulderink TA; Parker M; Bonow RO; Mehlman DJ
    Am J Cardiol; 1999 Dec; 84(11):1335-8. PubMed ID: 10614800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.
    Hensrud DD; Connolly HM; Grogan M; Miller FA; Bailey KR; Jensen MD
    Mayo Clin Proc; 1999 Dec; 74(12):1191-7. PubMed ID: 10593346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants].
    Goldstein SE; Levy Y; Shoenfeld Y
    Harefuah; 1998 Dec; 135(11):489-92, 568. PubMed ID: 10911459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anorectic therapy and valvular heart disease: a reappraisal.
    Silvestry FE; St John Sutton M
    Eur Heart J; 1999 Jul; 20(13):917-20. PubMed ID: 10361039
    [No Abstract]   [Full Text] [Related]  

  • 10. Further cases of valvular heart disease associated with fenfluramine-phentermine.
    Graham DJ; Green L
    N Engl J Med; 1997 Aug; 337(9):635. PubMed ID: 9280830
    [No Abstract]   [Full Text] [Related]  

  • 11. Severe heart valve disease on appetite suppressants.
    Prescrire Int; 1998 Feb; 7(33):19-20. PubMed ID: 10183395
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of selective serotonin reuptake inhibitor therapy on heart valves in patients exposed to benfluorex: a multicentre study.
    Maréchaux S; Jeu A; Jobic Y; Ederhy S; Donal E; Réant P; Abouth S; Arnasteen E; Boulanger J; Ennezat PV; Garban T; Szymanski C; Tribouilloy C
    Arch Cardiovasc Dis; 2013; 106(6-7):349-56. PubMed ID: 23876809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.
    Khan MA; Herzog CA; St Peter JV; Hartley GG; Madlon-Kay R; Dick CD; Asinger RW; Vessey JT
    N Engl J Med; 1998 Sep; 339(11):713-8. PubMed ID: 9731086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of multivalvular regurgitation after the cessation of fenfluramine and phentermine treatment.
    Cannistra LB; Cannistra AJ
    N Engl J Med; 1998 Sep; 339(11):771. PubMed ID: 9742026
    [No Abstract]   [Full Text] [Related]  

  • 15. Valvular heart disease in fenfluramine- phentermine-treated patients: a comparison with control patients.
    Wadden TA; Silvestry FE; Aber JL; Berkowitz RI; Foster GD; Sutton MG
    Obes Res; 1999 May; 7(3):309-10. PubMed ID: 10348504
    [No Abstract]   [Full Text] [Related]  

  • 16. Valvular heart disease associated with fenfluramine-phentermine.
    Spitzer WO
    N Engl J Med; 1997 Dec; 337(24):1774-5; author reply 1775-6. PubMed ID: 9411251
    [No Abstract]   [Full Text] [Related]  

  • 17. Diet pills redux.
    Curfman GD
    N Engl J Med; 1997 Aug; 337(9):629-30. PubMed ID: 9271487
    [No Abstract]   [Full Text] [Related]  

  • 18. Operation for anorexigen-associated valvular heart disease.
    Caccitolo JA; Connolly HM; Rubenson DS; Orszulak TA; Schaff HV
    J Thorac Cardiovasc Surg; 2001 Oct; 122(4):656-64. PubMed ID: 11581595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
    Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE
    N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Valvular heart disease and primary pulmonary hypertension associated with fenfluramine-phentermine].
    Wolf I; Mouallem M; Farfel Z
    Harefuah; 1998 Dec; 135(11):515-7. PubMed ID: 10911468
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.